<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SUMATRIPTAN- sumatriptan spray </strong><br>Sandoz Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Sumatriptan Nasal Spray safely and effectively.  See full prescribing information for Sumatriptan Nasal Spray.<br>Sumatriptan Nasal Spray<br>Initial U.S. Approval: 1992</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Sumatriptan is a serotonin (5-HT<span class="Sub">1B/1D</span>) receptor agonist (triptan) indicated for acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> in adults. (<a href="#ID_ce817064-c290-4278-8cc7-bbbf7106c6cf">1</a>) </p>
<p class="Highlighta"><span class="Underline">Limitations of Use:</span> </p>
<dl>
<dt>•</dt>
<dd>Use only if a clear diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> has been established. (<a href="#ID_ce817064-c290-4278-8cc7-bbbf7106c6cf">1</a>)</dd>
<dt>•</dt>
<dd>Not indicated for the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> therapy of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks. (<a href="#ID_ce817064-c290-4278-8cc7-bbbf7106c6cf">1</a>)</dd>
<dt>•</dt>
<dd>Not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span>. (<a href="#ID_ce817064-c290-4278-8cc7-bbbf7106c6cf">1</a>)</dd>
</dl>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>Single dose of 5 mg, 10 mg, or 20 mg of nasal spray. (<a href="#ID_de95f069-679c-40c2-8aff-2f25ac4138c7">2</a>)</dd>
<dt>•</dt>
<dd>A second dose should only be considered if some response to the first dose was observed. Separate doses by at least 2 hours. (<a href="#ID_de95f069-679c-40c2-8aff-2f25ac4138c7">2</a>)</dd>
<dt>•</dt>
<dd>Maximum dose in a 24-hour period: 40 mg. (<a href="#ID_de95f069-679c-40c2-8aff-2f25ac4138c7">2</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Nasal spray: 5 mg and 20 mg (<a href="#ID_14e1b3f0-7e23-4ab7-8de7-a89a638d48de">3</a>, <a href="#ID_2257241f-be37-4586-b100-6702b6ecb858">16</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>History of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> or coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> (<a href="#ID_e0e78751-2199-48f6-85e0-4351c6ff4870">4</a>)</dd>
<dt>•</dt>
<dd>Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders (<a href="#ID_e0e78751-2199-48f6-85e0-4351c6ff4870">4</a>)</dd>
<dt>•</dt>
<dd>History of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack, or hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (<a href="#ID_e0e78751-2199-48f6-85e0-4351c6ff4870">4</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral vascular disease</span> (<a href="#ID_e0e78751-2199-48f6-85e0-4351c6ff4870">4</a>)</dd>
<dt>•</dt>
<dd>Ischemic bowel disease (<a href="#ID_e0e78751-2199-48f6-85e0-4351c6ff4870">4</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled hypertension</span> (<a href="#ID_e0e78751-2199-48f6-85e0-4351c6ff4870">4</a>)</dd>
<dt>•</dt>
<dd>Recent (within 24 hours) use of another 5-HT1 agonist (e.g., another triptan) or of an ergotamine-containing medication. (<a href="#ID_e0e78751-2199-48f6-85e0-4351c6ff4870">4</a>)</dd>
<dt>•</dt>
<dd>Concurrent or recent (past 2 weeks) use of monoamine oxidase-A inhibitor. (<a href="#ID_e0e78751-2199-48f6-85e0-4351c6ff4870">4</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to sumatriptan (<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> seen). (<a href="#ID_e0e78751-2199-48f6-85e0-4351c6ff4870">4</a>)</dd>
<dt>•</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (<a href="#ID_e0e78751-2199-48f6-85e0-4351c6ff4870">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial ischemia</span>/<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> and Prinzmetal’s angina: Perform cardiac evaluation in patients with multiple cardiovascular risk factors. (<a href="#ID_6bab9875-1388-4bad-9274-d883a01979fc">5.1</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>: Discontinue Sumatriptan Nasal Spray if occurs. (<a href="#ID_5a47e602-06e2-4c91-a095-ab41b52d8b34">5.2</a>)</dd>
<dt>•</dt>
<dd>Chest/throat/neck/<span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">jaw pain</span>, tightness, pressure, or heaviness: Generally not associated with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>; evaluate for <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> in patients at high risk. (<a href="#ID_a773263a-8431-4384-93a9-45b8e325e2a8">5.3</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>: Discontinue Sumatriptan Nasal Spray if occurs. (<a href="#ID_c063f585-6d11-4460-a839-d8183f4d31c3">5.4</a>)</dd>
<dt>•</dt>
<dd>Gastrointestinal ischemic reactions and peripheral vasospastic reactions: Discontinue Sumatriptan Nasal Spray if occurs. (<a href="#ID_48966d7e-f2aa-470c-b25b-781d547b84ec">5.5</a>)</dd>
<dt>•</dt>
<dd>Medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>: Detoxification may be necessary. (<a href="#ID_181828d6-6937-4da8-9b8f-3cb951ffa02f">5.6</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span>: Discontinue Sumatriptan Nasal Spray if occurs. (<a href="#ID_2a7e07e8-88d5-4ad6-a378-6153780ec053">5.7</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>: Use with caution in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> or a lowered <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. (<a href="#ID_efe032c8-2e1b-4cc4-bcb8-98b84500baf1">5.11</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (≥1% and &gt;placebo) were <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span>, disorder/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> of nasal cavity/sinuses, throat <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, bad/unusual taste, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>. (<a href="#ID_9553cede-62b4-4771-a211-449626169476">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or <a href="#_Ref">www.fda.gov/medwatch.</a></span> </p>
</div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Pregnancy: Based on animal data, may cause fetal harm. (<a href="#ID_31a26d49-092a-4d5a-82bf-e1166cc012e6">8.1</a>) </p></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 6/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>, and Prinzmetal’s Angina </a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> </a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Chest, Throat, Neck, and/or <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">Jaw Pain</span>/Tightness/Pressure</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Cerebrovascular Events </a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span> Reactions</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Increase in Blood Pressure </a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Local Irritation</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience </a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience </a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Ergot-Containing Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Monoamine Oxidase-A Inhibitors</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Other 5-HT<span class="Sub">1</span> Agonists</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy </a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers </a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use </a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use </a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action </a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION </a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_ce817064-c290-4278-8cc7-bbbf7106c6cf"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Sumatriptan Nasal Spray is indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> in adults.</p>
<p>Limitations of Use:</p>
<dl>
<dt>•</dt>
<dd>Use only if a clear diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> has been established. If a patient has no response to the first <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack treated with Sumatriptan Nasal Spray, reconsider the diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> before Sumatriptan Nasal Spray is administered to treat any subsequent attacks.</dd>
<dt>•</dt>
<dd>Sumatriptan is not indicated for the prevention of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks.</dd>
<dt>•</dt>
<dd>Safety and effectiveness of Sumatriptan Nasal Spray have not been established for <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_de95f069-679c-40c2-8aff-2f25ac4138c7"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended adult dose of Sumatriptan Nasal Spray for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> is 5 mg, 10 mg, or 20 mg. The 20-mg dose may provide a greater effect than the 5-mg and 10-mg doses, but may have a greater risk of adverse reactions <span class="Italics">[see Clinical Studies (14)]</span>.</p>
<p>The 5-mg and 20-mg doses are given as a single spray in 1 nostril. The 10-mg dose may be achieved by the administration of a single 5-mg dose in each nostril. </p>
<p>If the <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> has not resolved by 2 hours after taking Sumatriptan Nasal Spray, or returns after a transient improvement, 1 additional dose may be administered at least 2 hours after the first dose. The maximum daily dose is 40 mg in a 24-hour period. </p>
<p>The safety of treating an average of more than 4 <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> in a 30‑day period has not been established.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_14e1b3f0-7e23-4ab7-8de7-a89a638d48de"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Unit dose nasal spray devices containing 5 mg or 20 mg sumatriptan.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_e0e78751-2199-48f6-85e0-4351c6ff4870"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Sumatriptan Nasal Spray is contraindicated in patients with:</p>
<dl>
<dt>•</dt>
<dd>Ischemic <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (CAD) (<span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or documented silent <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>) or coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, including Prinzmetal’s angina <span class="Italics">[see Warnings and Precautions (5.1)]</span>
</dd>
<dt>•</dt>
<dd>Wolff-Parkinson-White syndrome or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> associated with other cardiac accessory conduction pathway disorders <span class="Italics">[see Warnings and Precautions (5.2)]</span>
</dd>
<dt>•</dt>
<dd>History of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack (TIA), or history of hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> because these patients are at a higher risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> <span class="Italics">[see Warnings and Precautions (5.4)]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral vascular disease</span> <span class="Italics">[see Warnings and Precautions (5.5)]</span>
</dd>
<dt>•</dt>
<dd>Ischemic bowel disease <span class="Italics">[see Warnings and Precautions (5.5)]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled hypertension</span> <span class="Italics">[see Warnings and Precautions (5.8)]</span>
</dd>
<dt>•</dt>
<dd>Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine<span class="Sub">1 </span>(5-HT<span class="Sub">1</span>) agonist <span class="Italics">[see Drug Interactions (7.1, 7.3)]</span>
</dd>
<dt>•</dt>
<dd>Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent (within 2 weeks) use of an MAO-A inhibitor <span class="Italics">[see Drug Interactions (7.2) and Clinical Pharmacology (12.3)]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to sumatriptan (<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> seen) <span class="Italics">[see Warnings and Precautions (5.10)]</span>
</dd>
<dt>•</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Clinical Pharmacology (12.3)]</span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_fae835a0-fae5-42bd-b6e9-6acbbd42b5b0"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6bab9875-1388-4bad-9274-d883a01979fc"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>, and Prinzmetal’s Angina </h2>
<p class="First">The use of Sumatriptan Nasal Spray is contraindicated in patients with ischemic or vasospastic CAD. There have been rare reports of serious cardiac adverse reactions, including <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, occurring within a few hours following administration of Sumatriptan Nasal Spray. Some of these reactions occurred in patients without known CAD. Sumatriptan Nasal Spray may cause coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> (Prinzmetal’s angina), even in patients without a history of CAD.</p>
<p>Perform a cardiovascular evaluation in triptan-naive patients who have multiple cardiovascular risk factors (e.g., increased age, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, smoking, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, strong family history of CAD) prior to receiving Sumatriptan Nasal Spray. If there is evidence of CAD or coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, Sumatriptan Nasal Spray is contraindicated. For patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation, consider administering the first dose of Sumatriptan Nasal Spray in a medically supervised setting and performing an electrocardiogram (ECG) immediately following administration of Sumatriptan Nasal Spray. For such patients, consider periodic cardiovascular evaluation in intermittent long-term users of Sumatriptan Nasal Spray.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5a47e602-06e2-4c91-a095-ab41b52d8b34"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> </h2>
<p class="First">Life-threatening disturbances of cardiac rhythm, including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported within a few hours following the administration of 5-HT<span class="Sub">1</span> agonists. Discontinue Sumatriptan Nasal Spray if these disturbances occur. Sumatriptan Nasal Spray is contraindicated in patients with Wolff-Parkinson-White syndrome or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> associated with other cardiac accessory conduction pathway disorders.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a773263a-8431-4384-93a9-45b8e325e2a8"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Chest, Throat, Neck, and/or <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">Jaw Pain</span>/Tightness/Pressure</h2>
<p class="First">Sensations of tightness, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, pressure, and heaviness in the precordium, throat, neck, and jaw may occur after treatment with Sumatriptan Nasal Spray and are usually non-cardiac in origin. However, perform a cardiac evaluation if these patients are at high cardiac risk. The use of Sumatriptan Nasal Spray is contraindicated in patients with CAD and those with Prinzmetal’s <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">variant angina</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c063f585-6d11-4460-a839-d8183f4d31c3"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Cerebrovascular Events </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> have occurred in patients treated with 5-HT<span class="Sub">1</span> agonists, and some have resulted in fatalities. In a number of cases, it appears possible that the cerebrovascular events were primary, the 5-HT<span class="Sub">1</span> agonist having been administered in the incorrect belief that the symptoms experienced were a consequence of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> when they were not. Also, patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> may be at increased risk of certain cerebrovascular events (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, TIA). Discontinue Sumatriptan Nasal Spray if a cerebrovascular event occurs.</p>
<p>Before treating <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> in patients not previously diagnosed as migraineurs, and in migraineurs who present with atypical symptoms, exclude other potentially serious neurological conditions. Sumatriptan Nasal Spray is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or TIA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_48966d7e-f2aa-470c-b25b-781d547b84ec"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span> Reactions</h2>
<p class="First">Sumatriptan Nasal Spray may cause non-coronary vasospastic reactions, such as peripheral vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, gastrointestinal vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> and <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> (presenting with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>), <span class="product-label-link" type="condition" conceptid="4044745" conceptname="Splenic infarction">splenic infarction</span>, and Raynaud’s syndrome. In patients who experience symptoms or signs suggestive of non-<span class="product-label-link" type="condition" conceptid="4127089" conceptname="Coronary artery spasm">coronary vasospasm</span> reaction following the use of any 5-HT<span class="Sub">1</span> agonist, rule out a vasospastic reaction before using additional Sumatriptan Nasal Spray.</p>
<p>Reports of transient and permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> and significant partial <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span> have been reported with the use of 5‑HT<span class="Sub">1</span> agonists. Since visual disorders may be part of a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack, a causal relationship between these events and the use of 5-HT<span class="Sub">1</span> agonists have not been clearly established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_181828d6-6937-4da8-9b8f-3cb951ffa02f"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></h2>
<p class="First">Overuse of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> drugs (e.g., ergotamine, triptans, opioids, or combination of these drugs for 10 or more days per month) may lead to exacerbation of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>). Medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> may present as <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-like daily <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> or as a marked increase in frequency of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks. Detoxification of patients, including withdrawal of the overused drugs, and treatment of withdrawal symptoms (which often includes a transient worsening of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>) may be necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2a7e07e8-88d5-4ad6-a378-6153780ec053"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> may occur with Sumatriptan Nasal Spray, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors <span class="Italics">[see Drug Interactions (7.4)]</span>. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> symptoms may include <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular aberrations (e.g., <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>), and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>). The onset of symptoms usually occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. Discontinue Sumatriptan Nasal Spray if <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> is suspected.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fb66690c-3c20-4b99-8de9-e3846340ea90"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Increase in Blood Pressure </h2>
<p class="First">Significant elevation in blood pressure, including <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span> with acute impairment of organ systems, has been reported on rare occasions in patients treated with 5-HT<span class="Sub">1</span> agonists, including patients without a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Monitor blood pressure in patients treated with sumatriptan. Sumatriptan Nasal Spray is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f9c5adbd-8c3b-4602-8dee-5da34c6604d7"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Local Irritation</h2>
<p class="First">Local irritative symptoms such as burning, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, discharge, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or soreness were reported in approximately 5% of patients in controlled clinical trials and were noted to be severe in about 1%. The symptoms were transient and generally resolved in less than 2 hours. Limited examinations of the nose and throat did not reveal any clinically noticeable injury in these patients. The consequences of extended and repeated use of Sumatriptan Nasal Spray on the nasal and/or respiratory mucosa have not been systematically evaluated in patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4b288c3d-15e5-4642-8767-112bd12fabb9"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></h2>
<p class="First">Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have occurred in patients receiving sumatriptan. Such reactions can be life threatening or fatal. In general, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens. Sumatriptan Nasal Spray is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to sumatriptan.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_efe032c8-2e1b-4cc4-bcb8-98b84500baf1"></a><a name="section-5.11"></a><p></p>
<h2>5.11 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> have been reported following administration of sumatriptan. Some have occurred in patients with either a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or concurrent conditions predisposing to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. There are also reports in patients where no such predisposing factors are apparent. Sumatriptan Nasal Spray should be used with caution in patients with a history of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> or conditions associated with a lowered <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_36448d87-e372-4042-9d75-540a44efd428"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in more detail in other sections of the prescribing information:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and Prinzmetal’s angina <span class="Italics">[see Warnings and Precautions (5.1)]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> <span class="Italics">[see Warnings and Precautions (5.2)]</span>
</dd>
<dt>•</dt>
<dd>Chest, throat, neck, and/or <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">jaw pain</span>/tightness/pressure <span class="Italics">[see Warnings and Precautions (5.3)]</span>
</dd>
<dt>•</dt>
<dd>Cerebrovascular events <span class="Italics">[see Warnings and Precautions (5.4)]</span>
</dd>
<dt>•</dt>
<dd>Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> reactions <span class="Italics">[see Warnings and Precautions (5.5)]</span>
</dd>
<dt>•</dt>
<dd>Medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> <span class="Italics">[see Warnings and Precautions (5.6)]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> <span class="Italics">[see Warnings and Precautions (5.7)]</span>
</dd>
<dt>•</dt>
<dd>Increase in blood pressure <span class="Italics">[see Warnings and Precautions (5.8)]</span>
</dd>
<dt>•</dt>
<dd>Local irritation <span class="Italics">[see Warnings and Precautions (5.9)]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> <span class="Italics">[see Contraindications (4) and Warnings and Precautions (5.10)]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> <span class="Italics">[see Warnings and Precautions (5.11)]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9553cede-62b4-4771-a211-449626169476"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience </h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>Table 1 lists adverse reactions that occurred in worldwide placebo-controlled clinical trials in 3,419 patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. Only treatment-emergent adverse reactions that occurred at a frequency of 1% or more in the group treated with Sumatriptan Nasal Spray 20 mg and that occurred at a frequency greater than the placebo group are included in Table 1.</p>
<a name="_RefID0ENHAE"></a><table width="100%">
<caption><span>Table 1. Adverse Reactions Reported by at Least 1% of Patients and at a Greater Frequency Than Placebo in Controlled <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Clinical Trials</span></caption>
<col width="47%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="10%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="4" valign="bottom"><p class="First"><span class="Bold">Percent of Patients Reporting</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Sumatriptan</span></p>
<p><span class="Bold">Nasal Spray</span></p>
<p><span class="Bold">5 mg</span></p>
<p><span class="Bold">(n = 496)</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Sumatriptan</span></p>
<p><span class="Bold">Nasal Spray</span></p>
<p><span class="Bold">10 mg</span></p>
<p><span class="Bold">(n = 1,007)</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Sumatriptan</span></p>
<p><span class="Bold">Nasal Spray</span></p>
<p><span class="Bold">20 mg</span></p>
<p><span class="Bold">(n = 1,212)</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">(n = 704)</span></p>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><p class="First">Atypical sensations</p></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">Burning sensation</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">0.4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.1</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Ear, nose, and throat</p></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>Disorder/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> of nasal cavity/sinuses</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">2.8</p></td>
<td class="Rrule" align="center"><p class="First">2.5</p></td>
<td class="Rrule" align="center"><p class="First">3.8</p></td>
<td class="Rrule" align="center"><p class="First">2.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd>Throat <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">0.8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.8</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2.4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.9</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Gastrointestinal</p></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">12.2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">11.0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">13.5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">11.3</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Neurological</p></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt> </dt>
<dd>Bad/unusual taste</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">13.5</p></td>
<td class="Rrule" align="center"><p class="First">19.3</p></td>
<td class="Rrule" align="center"><p class="First">24.5</p></td>
<td class="Rrule" align="center"><p class="First">1.7</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">1.0</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1.4</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.9</p></td>
</tr>
</tbody>
</table>
<p>The incidence of adverse reactions in controlled clinical trials was not affected by gender, weight, or age of the patients; use of <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> medications; or presence of <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>. There were insufficient data to assess the impact of race on the incidence of adverse reactions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4090cfa2-cd95-4225-811d-4cc67cd08cf7"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience </h2>
<p class="First">The following adverse reactions have been identified during postapproval use of Sumatriptan Tablets, Sumatriptan Nasal Spray, and Sumatriptan Injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reactions have been chosen for inclusion due to either their seriousness, frequency of reporting, or causal connection to sumatriptan or a combination of these factors.</p>
<p><span class="Underline">Cardiovascular</span>: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>.</p>
<p><span class="Underline">Neurological:</span> <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_ae9b75fb-b60b-47bd-bbbf-f329e9a6d7f4"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f608e447-c4f5-4745-bae9-8e3dbebdb8d1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Ergot-Containing Drugs</h2>
<p class="First">Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and Sumatriptan Nasal Spray within 24 hours of each other is contraindicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e1f08a23-e717-4044-9946-dbffa35e20f2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Monoamine Oxidase-A Inhibitors</h2>
<p class="First">MAO-A inhibitors increase systemic exposure by up to 7-fold. Therefore, the use of Sumatriptan Nasal Spray in patients receiving MAO-A inhibitors is contraindicated <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5635b27e-cfa6-4951-9d2c-c12f32eab960"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Other 5-HT<span class="Sub">1</span> Agonists</h2>
<p class="First">Because their vasospastic effects may be additive, co-administration of Sumatriptan Nasal Spray and other 5-HT<span class="Sub">1</span> agonists (e.g., triptans) within 24 hours of each other is contraindicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e8ae82dc-aaa4-4221-91a7-ac1ba4f209a0"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> have been reported during co-administration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors <span class="Italics">[see Warnings and Precautions (5.7)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_65b7ef2a-ce82-4afe-98c2-01458c3d7c8e"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_31a26d49-092a-4d5a-82bf-e1166cc012e6"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy </h2>
<p class="First"><span class="Underline">Pregnancy Category C:</span> There are no adequate and well-controlled trials in pregnant women. In developmental toxicity studies in rats and rabbits, oral administration of sumatriptan to pregnant animals was associated with embryolethality, fetal abnormalities, and pup mortality. When administered by the intravenous route to pregnant rabbits, sumatriptan was embryolethal. Developmental toxicity studies of sumatriptan by the intranasal route have not been conducted. Sumatriptan Nasal Spray should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>Oral administration of sumatriptan to pregnant rats during the period of organogenesis resulted in an increased incidence of fetal blood vessel (cervicothoracic and umbilical) abnormalities. The highest no-effect dose for embryofetal developmental toxicity in rats was 60 mg/kg/day. Oral administration of sumatriptan to pregnant rabbits during the period of organogenesis resulted in increased incidences of embryolethality and fetal cervicothoracic vascular and skeletal abnormalities. Intravenous administration of sumatriptan to pregnant rabbits during the period of organogenesis resulted in an increased incidence of embryolethality. The highest oral and intravenous no-effect doses for developmental toxicity in rabbits were 15 and 0.75 mg/kg/day, respectively.</p>
<p>Oral administration of sumatriptan to rats prior to and throughout gestation resulted in embryofetal toxicity (decreased body weight, decreased ossification, increased incidence of skeletal abnormalities). The highest no-effect dose was 50 mg/kg/day. In offspring of pregnant rats treated orally with sumatriptan during organogenesis, there was a decrease in pup survival. The highest no-effect dose for this effect was 60 mg/kg/day. Oral treatment of pregnant rats with sumatriptan during the latter part of gestation and throughout lactation resulted in a decrease in pup survival. The highest no-effect dose for this finding was 100 mg/kg/day.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_a382867f-cfd2-44f3-964b-d01e6575a072"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers </h2>
<p class="First">Sumatriptan is excreted in human milk following subcutaneous administration. Infant exposure to sumatriptan can be minimized by avoiding breastfeeding for 12 hours after treatment with Sumatriptan Nasal Spray.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_a5e827b3-1d0f-463a-b156-e15bc2e43a72"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use </h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established. Sumatriptan Nasal Spray is not recommended for use in patients younger than 18 years of age.</p>
<p>Two controlled clinical trials evaluated Sumatriptan Nasal Spray (5 to 20 mg) in 1,248 adolescent migraineurs aged 12 to 17 years who treated a single attack. The trials did not establish the efficacy of Sumatriptan Nasal Spray compared with placebo in the treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> in adolescents. Adverse reactions observed in these clinical trials were similar in nature to those reported in clinical trials in adults.</p>
<p>Five controlled clinical trials (2 single-attack trials, 3 multiple-attack trials) evaluating oral sumatriptan (25 to 100 mg) in pediatric patients aged 12 to 17 years enrolled a total of 701 adolescent migraineurs. These trials did not establish the efficacy of oral sumatriptan compared with placebo in the treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> in adolescents. Adverse reactions observed in these clinical trials were similar in nature to those reported in clinical trials in adults. The frequency of all adverse reactions in these patients appeared to be both dose- and age-dependent, with younger patients reporting reactions more commonly than older adolescents. </p>
<p>Postmarketing experience documents that serious adverse reactions have occurred in the pediatric population after use of subcutaneous, oral, and/or intranasal sumatriptan. These reports include reactions similar in nature to those reported rarely in adults, including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, visual loss, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. A <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> has been reported in a 14‑year‑old male following the use of oral sumatriptan; clinical signs occurred within 1 day of drug administration. Clinical data to determine the frequency of serious adverse reactions in pediatric patients who might receive subcutaneous, oral, or intranasal sumatriptan are not presently available. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_1cc4c31e-c492-4fee-a817-b05231735f8d"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use </h2>
<p class="First">Clinical trials of Sumatriptan Nasal Spray did not include sufficient numbers of patients aged 65 and older to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.</p>
<p>A cardiovascular evaluation is recommended for geriatric patients who have other cardiovascular risk factors (e.g., <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, smoking, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, strong family history of CAD) prior to receiving Sumatriptan Nasal Spray <span class="Italics">[see Warnings and Precautions (5.1)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_c83fcf93-87dd-400a-9f59-b12cc8515aa7"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">In clinical trials, the highest single doses of Sumatriptan Nasal Spray administered without significant reactions were 40 mg to 12 volunteers and 40 mg to 85 subjects with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, which is twice the highest single recommended dose. In addition, 12 volunteers were administered a total daily dose of 60 mg (20 mg 3 times daily) for 3.5 days without significant adverse reactions.</p>
<p><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> in animals has been fatal and has been heralded by <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>, inactivity, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> of the extremities, abnormal respiration, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, and <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>.</p>
<p>The elimination half‑life of sumatriptan is approximately 2 hours <span class="Italics">[see Clinical Pharmacology (12.3)]</span>, and therefore monitoring of patients after <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with Sumatriptan Nasal Spray should continue for at least 10 hours or while symptoms or signs persist.</p>
<p>It is unknown what effect hemodialysis or peritoneal dialysis has on the serum concentrations of sumatriptan.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_10823826-be3e-4d0d-8710-b1b6d4f88859"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Sumatriptan Nasal Spray contains sumatriptan, a selective 5-HT<span class="Sub">1B/1D</span> receptor agonist. Sumatriptan is chemically designated as 3-[2-(dimethylamino)ethyl]-N-methyl-indole-5-methanesulfonamide, and it has the following structure:</p>
<div class="Figure">
<a name="id7228441"></a><img alt="sumatriptan chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6c95caa4-812e-4e47-bcfc-c641c00db3f7&amp;name=sumatriptan-image-01.jpg">
</div>
<p>The empirical formula is C<span class="Sub">14</span>H<span class="Sub">21</span>N<span class="Sub">3</span>O<span class="Sub">2</span>S, representing a molecular weight of 295.4. Sumatriptan is a white to off-white powder that is readily soluble in water and in saline. </p>
<p>Each Sumatriptan Nasal Spray contains 5 or 20 mg of sumatriptan in a 100-μL unit dose aqueous buffered solution containing monobasic potassium phosphate NF, anhydrous dibasic sodium phosphate USP, sulfuric acid NF, sodium hydroxide NF, and purified water USP. The pH of the solution is approximately 5.5. The <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of the solution is 372 or 742 mOsmol for the 5- and 20-mg Sumatriptan Nasal Spray, respectively.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_1482c499-f102-4659-b51a-b7475264041c"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_304e978c-eec9-436e-a69a-8ec52a654d50"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action </h2>
<p class="First">Sumatriptan binds with high affinity to human cloned 5-HT<span class="Sub">1B/1D</span> receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> through agonist effects at the 5‑HT<span class="Sub">1B/1D</span> receptors on intracranial blood vessels  and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_dcd467a6-8765-4670-ab80-0a76ed3ec37c"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><span class="Underline">Blood Pressure:</span> Significant elevation in blood pressure, including <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>, has been reported in patients with and without a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> <span class="Italics">[see Warnings and Precautions (5.8)]</span>.</p>
<p><span class="Underline">Peripheral (Small) Arteries:</span> In healthy volunteers (N = 18), a trial evaluating the effects of sumatriptan on peripheral (small vessel) arterial reactivity failed to detect a clinically significant increase in peripheral resistance.</p>
<p><span class="Underline">Heart Rate</span>: Transient increases in blood pressure observed in some patients in clinical trials carried out during sumatriptan’s development as a treatment for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> were not accompanied by any clinically significant changes in heart rate.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_4bf9b7ab-358d-43d9-b5ce-5b0f25e9fc26"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Absorption and Bioavailability: In a trial of 20 female volunteers, the mean maximum concentration following a 5- and 20-mg intranasal dose was 5 and 16 ng/mL, respectively. The mean C<span class="Sub">max</span> following a 6‑mg subcutaneous injection is 71 ng/mL (range: 49 to 110 ng/mL). The mean C<span class="Sub">max</span> is 18 ng/mL (range: 7 to 47 ng/mL) following oral dosing with 25 mg and 51 ng/mL (range: 28 to 100 ng/mL) following oral dosing with 100 mg of sumatriptan. In a trial of 24 male volunteers, the bioavailability relative to subcutaneous injection was low, approximately 17%, primarily due to presystemic metabolism and partly due to incomplete absorption.</p>
<p>Clinical and pharmacokinetic data indicate that administration of two 5-mg doses, 1 dose in each nostril, is equivalent to administration of a single 10-mg dose in 1 nostril.</p>
<p><span class="Underline">Distribution:</span> Protein binding, determined by equilibrium dialysis over the concentration range of 10 to 1,000 ng/mL, is low, approximately 14% to 21%. The effect of sumatriptan on the protein binding of other drugs has not been evaluated. The apparent volume of distribution is 2.7 L/kg.</p>
<p><span class="Underline">Metabolism:</span> In vitro studies with human microsomes suggest that sumatriptan is metabolized by MAO, predominantly the A isoenzyme. Most of a radiolabeled dose of sumatriptan excreted in the urine is the major metabolite indole acetic acid (IAA) or the IAA glucuronide, both of which are inactive.</p>
<p><span class="Underline">Elimination:</span> The elimination half-life of sumatriptan administered as a nasal spray is approximately 2 hours, similar to the half-life seen after subcutaneous injection. Only 3% of the dose is excreted in the urine as unchanged sumatriptan; 42% of the dose is excreted as the major metabolite, the indole acetic acid analogue of sumatriptan. The total plasma clearance is approximately 1,200 mL/min.</p>
<p><span class="Underline">Special Populations:</span><span class="Italics">Age:</span> The pharmacokinetics of sumatriptan in the elderly (mean age: 72 years, 2 males and 4 females) and in subjects with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (mean age: 38 years, 25 males and 155 females) were similar to that in healthy male subjects (mean age: 30 years). Intranasal sumatriptan has not been evaluated for age differences.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of sumatriptan has not been examined.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> The effect of mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> on the pharmacokinetics of the intranasal formulation of sumatriptan has not been evaluated. Sumatriptan bioavailability following intranasal administration is 17%, similar to that after oral administration (15%). Following oral administration, an approximately 70% increase in Cmax and AUC was observed in one small trial of patients with moderate liver impairment (n = 8) matched for sex, age and weight with healthy subjects (n = 8). Similar changes can be expected following intranasal administration.</p>
<p>The pharmacokinetics of sumatriptan in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> has not been studied. The use of Sumatriptan Nasal Spray in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is contraindicated <span class="Italics">[see Contraindications (4)]</span>.</p>
<p><span class="Italics">Race:</span> The systemic clearance and C<span class="Sub">max</span> of subcutaneous sumatriptan were similar in black (n = 34) and Caucasian (n = 38) healthy male subjects. Intranasal sumatriptan has not been evaluated for race differences.</p>
<p><span class="Underline">Drug Interaction Studies:</span><span class="Italics">Monoamine Oxidase-A Inhibitors:</span> Treatment with MAO-A inhibitors generally leads to an increase of sumatriptan plasma levels <span class="Italics">[see Contraindications (4) and Drug Interactions (7.2)]</span>. MAO inhibitors interaction studies have not been performed with intranasal sumatriptan. </p>
<p>Due to gut and hepatic metabolic first-pass effects, the increase of systemic exposure after co-administration of an MAO-A inhibitor with oral sumatriptan is greater than after co-administration of the MAO inhibitors with subcutaneous sumatriptan. The effects of an MAO inhibitor on systemic exposure after intranasal sumatriptan would be expected to be greater than the effect after subcutaneous sumatriptan but smaller than the effect after oral sumatriptan because only swallowed drug would be subject to first-pass effects.</p>
<p>In a trial of 14 healthy females, pretreatment with an MAO-A inhibitor decreased the clearance of subcutaneous sumatriptan, resulting in a 2-fold increase in the area under the sumatriptan plasma concentration-time curve (AUC), corresponding to a 40% increase in elimination half‑life.</p>
<p>A small trial evaluating the effect of pretreatment with an MAO-A inhibitor on the bioavailability from a 25-mg oral sumatriptan tablet resulted in an approximately 7-fold increase in systemic exposure.</p>
<p><span class="Italics">Xylometazoline:</span> An in vivo drug interaction trial indicated that 3 drops of xylometazoline (0.1% w/v), a decongestant, administered 15 minutes prior to a 20-mg nasal dose of sumatriptan did not alter the pharmacokinetics of sumatriptan.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_db11cda3-0b93-445a-b662-c379e94001d1"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_42683d6d-f694-44ac-b25b-20845e5f4727"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Underline">Carcinogenesis:</span> In carcinogenicity studies in mouse and rat in which sumatriptan was administered orally for 78 and 104 weeks, respectively, there was no evidence in either species of an increase in tumors related to sumatriptan administration.</p>
<p>Carcinogenicity studies of sumatriptan using the nasal route have not been conducted.</p>
<p><span class="Underline">Mutagenesis:</span> Sumatriptan was negative in in vitro(bacterial reverse mutation [Ames], gene cell mutation in Chinese hamster V79/HGPRT, chromosomal aberration in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>) and in vivo (rat micronucleus) assays.</p>
<p><span class="Underline">Impairment of Fertility:</span> When sumatriptan was administered by subcutaneous injection to male and female rats prior to and throughout the mating period, there was no evidence of impaired fertility at doses up to 60 mg/kg/day. When sumatriptan (5, 50, or 500 mg/kg/day) was administered orally to male and female rats prior to and throughout the mating period, there was a treatment-related decrease in fertility secondary to a decrease in mating in animals treated with doses greater than 5 mg/kg/day. It is not clear whether this finding was due to an effect on males or females or both.</p>
<p>Fertility studies of sumatriptan using the intranasal route have not been conducted.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="ID_98c65425-66ec-4f8c-b3a9-ac846145e53f"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">Corneal Opacities: Dogs receiving oral sumatriptan developed corneal opacities and defects in the corneal epithelium. Corneal opacities were seen at the lowest dose tested, 2 mg/kg/day, and were present after 1 month of treatment. Defects in the corneal epithelium were noted in a 60‑week study. Earlier examinations for these toxicities were not conducted and no-effect doses were not established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_4601bb90-74fe-4d9b-98fe-af911bbf0674"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The efficacy of Sumatriptan Nasal Spray in the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> was demonstrated in 8, randomized, double-blind, placebo-controlled trials, of which 5 used the recommended dosing regimen and used the marketed formulation. Patients enrolled in these 5 trials were predominately female (86%) and Caucasian (95%), with a mean age of 41 years (range of 18 to 65 years). Patients were instructed to treat a moderate to severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> response, defined as a reduction in <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> severity from moderate or severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> to mild or no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, was assessed up to 2 hours after dosing. Associated symptoms such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, and <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span> were also assessed. Maintenance of response was assessed for up to 24 hours postdose. A second dose of Sumatriptan Nasal Spray or other medication was allowed 2 to 24 hours after the initial treatment for recurrent <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. The frequency and time to use of these additional treatments were also determined. In all trials, doses of 10 and 20 mg were compared with placebo in the treatment of 1 to 3 <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks. Patients received doses as a single spray into 1 nostril. In 2 trials, a 5-mg dose was also evaluated.</p>
<p>In all 5 trials utilizing the market formulation and recommended dosage regimen, the percentage of patients achieving <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response 2 hours after treatment was significantly greater among patients receiving Sumatriptan Nasal Spray at all doses (with one exception) compared with those who received placebo. In 4 of the 5 trials, there was a statistically significant greater percentage of patients with <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response at 2 hours in the 20-mg group when compared with the lower dose groups (5 and 10 mg). There were no statistically significant differences between the 5- and 10-mg dose groups in any trial. The results from the 5 controlled clinical trials are summarized in Table 2. Note that, in general, comparisons of results obtained in trials conducted under different conditions by different investigators with different samples of patients are ordinarily unreliable for purposes of quantitative comparison.</p>
<a name="_RefID0E1BAG"></a><table width="100%">
<caption><span>Table 2. Percentage of Patients With <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> Response (No or Mild <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>) 2 Hours Following Treatment</span></caption>
<col width="14%">
<col width="24%">
<col width="23%">
<col width="23%">
<col width="17%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">Sumatriptan</span></p>
<p><span class="Bold">Nasal Spray</span></p>
<p><span class="Bold">5 mg</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">Sumatriptan</span></p>
<p><span class="Bold">Nasal Spray</span></p>
<p><span class="Bold">10 mg</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">Sumatriptan</span></p>
<p><span class="Bold">Nasal Spray</span></p>
<p><span class="Bold">20 mg</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Trial 1</p></td>
<td class="Rrule" align="center"><p class="First">49%<span class="Sup">a</span></p></td>
<td class="Rrule" align="center"><p class="First">46%<span class="Sup">a</span></p></td>
<td class="Rrule" align="center"><p class="First">64%<span class="Sup">a,b,c</span></p></td>
<td class="Rrule" align="center"><p class="First">25%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 121)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 112)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 118)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 63)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Trial 2</p></td>
<td class="Rrule" align="center"><p class="First">Not applicable</p></td>
<td class="Rrule" align="center"><p class="First">44%<span class="Sup">a</span></p></td>
<td class="Rrule" align="center"><p class="First">55%<span class="Sup">a,b</span></p></td>
<td class="Rrule" align="center"><p class="First">25%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 273)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 277)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 138)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Trial 3</p></td>
<td class="Rrule" align="center"><p class="First">Not applicable</p></td>
<td class="Rrule" align="center"><p class="First">54%<span class="Sup">a</span></p></td>
<td class="Rrule" align="center"><p class="First">63%<span class="Sup">a</span></p></td>
<td class="Rrule" align="center"><p class="First">35%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 106)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 202)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 100)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Trial 4</p></td>
<td class="Rrule" align="center"><p class="First">Not applicable</p></td>
<td class="Rrule" align="center"><p class="First">43%</p></td>
<td class="Rrule" align="center"><p class="First">62%<span class="Sup">a,b</span></p></td>
<td class="Rrule" align="center"><p class="First">29%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 106)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 215)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 112)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Trial 5<span class="Sup">d</span></p></td>
<td class="Rrule" align="center"><p class="First">45%<span class="Sup">a</span></p></td>
<td class="Rrule" align="center"><p class="First">53%<span class="Sup">a</span></p></td>
<td class="Rrule" align="center"><p class="First">60%<span class="Sup">a,c</span></p></td>
<td class="Rrule" align="center"><p class="First">36%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 296)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 291)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 286)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">(n = 198)</p></td>
</tr>
</tbody>
</table>
<dl>
<dt> </dt>
<dd>
<span class="Sup">a</span><span class="Italics">	P</span>	&lt;0.05 in comparison with placebo.</dd>
<dt> </dt>
<dd>
<span class="Sup">b</span><span class="Italics">	P</span>	&lt;0.05 in comparison with 10 mg.</dd>
<dt> </dt>
<dd>
<span class="Sup">c</span><span class="Italics">	P</span>	&lt;0.05 in comparison with 5 mg.</dd>
<dt> </dt>
<dd>
<span class="Sup">d</span>	Data are for attack 1 only of multi-attack trial for comparison.</dd>
</dl>
<p>The estimated probability of achieving an initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response over the 2 hours following treatment is depicted in Figure 1.</p>
<p><span class="Bold">Figure 1. Estimated Probability of Achieving Initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> Response Within 120 Minutes<span class="Sup">a</span></span></p>
<div class="Figure">
<a name="id7228453"></a><img alt="Figure 1. estimated probability of initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response within 120 minutes" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6c95caa4-812e-4e47-bcfc-c641c00db3f7&amp;name=sumatriptan-image-02.jpg">
</div>
<dl>
<dt> </dt>
<dd>
<span class="Sup">a</span>	The figure shows the probability over time of obtaining <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response (no or mild <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>) following treatment with intranasal sumatriptan. The averages displayed are based on pooled data from the 5 clinical controlled trials providing evidence of efficacy. Kaplan-Meier plot with patients not achieving response within 120 minutes censored to 120 minutes.</dd>
</dl>
<p>For patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-associated <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, and <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span> at baseline, there was a lower incidence of these symptoms at 2 hours following administration of Sumatriptan Nasal Spray compared with placebo.</p>
<p>Two to 24 hours following the initial dose of study treatment, patients were allowed to use additional treatment for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief in the form of a second dose of study treatment or other medication. The estimated probability of patients taking a second dose or other medication for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> over the 24 hours following the initial dose of study treatment is summarized in Figure 2.</p>
<p><span class="Bold">Figure 2. The Estimated Probability of Patients Taking a Second Dose or Other Medication for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Over the 24 Hours Following the Initial Dose of Study Treatment<span class="Sup">a</span></span></p>
<div class="Figure">
<a name="id7228464"></a><img alt="figure 2. probability of patients needing second dose or additional medication" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6c95caa4-812e-4e47-bcfc-c641c00db3f7&amp;name=sumatriptan-image-03.jpg">
</div>
<dl>
<dt> </dt>
<dd>
<span class="Sup">a</span>Kaplan-Meier plot based on data obtained in the 3 clinical controlled trials providing evidence of efficacy with patients not using additional treatments censored to 24 hours. Plot also includes patients who had no response to the initial dose. No remedication was allowed within 2 hours postdose.</dd>
</dl>
<p>There is evidence that doses above 20 mg do not provide a greater effect than 20 mg. There was no evidence to suggest that treatment with sumatriptan was associated with an increase in the severity of recurrent <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>. The efficacy of Sumatriptan Nasal Spray was unaffected by presence of <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>; duration of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> prior to treatment; gender, age, or weight of the subject; or concomitant use of common <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> drugs (e.g., beta-blockers, calcium channel blockers, tricyclic antidepressants). There were insufficient data to assess the impact of race on efficacy.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_2257241f-be37-4586-b100-6702b6ecb858"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Sumatriptan Nasal Spray 5 mg (NDC 0781-6524-86) and 20 mg (NDC 0781-6523-86) are each supplied in boxes of 6 nasal spray devices. Each unit dose spray supplies 5 mg and 20 mg, respectively, of sumatriptan.</p>
<p>Store between 2°C and 30°C (36°F and 86°F). Protect from light.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_668117c7-59bc-4f9f-bb8f-b0b2fe868a94"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION </h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (Patient Information). </p>
<p><span class="Underline">Risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span>, Prinzmetal’s Angina, Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span>-Related Events, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>, and Cerebrovascular Events:</span> Inform patients that Sumatriptan Nasal Spray may cause serious cardiovascular side effects such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. Although serious cardiovascular events can occur without warning symptoms, patients should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, irregular heartbeat, significant <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and slurring of speech and should ask for medical advice if any indicative sign or symptoms are observed. Apprise patients of the importance of this follow-up <span class="Italics">[see Warnings and Precautions (5.1, 5.2, 5.4, 5.5, 5.8)]</span>.</p>
<p><span class="Underline">Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></span>: Inform patients that anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have occurred in patients receiving Sumatriptan Nasal Spray. Such reactions can be life threatening or fatal. In general, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens <span class="Italics">[see Contraindications (4) and Warnings and Precautions (5.10)]</span>.</p>
<p><span class="Underline">Concomitant Use With Other Triptans or Ergot Medications</span>: Inform patients that use of Sumatriptan Nasal Spray within 24 hours of another triptan or an ergot-type medication (including dihydroergotamine or methysergide) is contraindicated <span class="Italics">[see Contraindications (4) and Drug Interactions (7.1, 7.3)]</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>: </span>Caution patients about the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with the use of Sumatriptan Nasal Spray or other triptans, particularly during combined use with SSRIs, SNRIs, TCAs, and MAO inhibitors <span class="Italics">[see Warnings and Precautions (5.7) and Drug Interactions (7.4)].</span></p>
<p><span class="Underline">Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>: </span>Inform patients that use of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> drugs for 10 or more days per month may lead to an exacerbation of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and encourage patients to record <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> frequency and drug use (e.g., by keeping a <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> diary) <span class="Italics">[see Warnings and Precautions (5.6)]</span>.</p>
<p><span class="Underline">Pregnancy: </span>Inform patients that Sumatriptan Nasal Spray should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus <span class="Italics">[see Use in Specific Populations (8.1)]</span>.</p>
<p><span class="Underline">Nursing Mothers:</span> Advise patients to notify their healthcare provider if they are breastfeeding or plan to breastfeed <span class="Italics">[see Use in Specific Populations (8.3)]</span>.</p>
<p><span class="Underline">Ability to Perform Complex Tasks:</span> Treatment with Sumatriptan Nasal Spray may cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; instruct patients to evaluate their ability to perform complex tasks after administration of Sumatriptan Nasal Spray.</p>
<p><span class="Underline">Local Irritation:</span> Inform patients that they may experience local irritation of their nose and throat. The symptoms will generally resolve in less than 2 hours.</p>
<p><span class="Underline">How to Use Sumatriptan Nasal Spray:</span> Provide patients instruction on the proper use of Sumatriptan Nasal Spray. Caution patients to avoid spraying the contents of the device in their eyes.</p>
<p>Manufactured by</p>
<p>GlaxoSmithKline Manufacturing S.p.A. </p>
<p>for Sandoz Inc. </p>
<p>Princeton, NJ  08540</p>
<p>SNS-SZ:4PI</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_82d8c149-37b4-4a16-84da-9c2fac1b3cb4"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Patient Information</span></p>
<p><span class="Bold">Sumatriptan Nasal Spray</span></p>
<p>(soo" ma trip' tan)</p>
<p>Read this Patient Information before you start using Sumatriptan Nasal Spray and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment.</p>
<p><span class="Bold">What is the most important information I should know about Sumatriptan Nasal Spray?</span></p>
<p><span class="Bold">Sumatriptan Nasal Spray can cause serious side effects, including:</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attack</span> and other heart problems. Heart problems may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></p>
<p><span class="Bold">Stop taking Sumatriptan Nasal Spray and get emergency medical help right away if you have any of the following symptoms of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>: </span></p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> in the center of your chest that lasts for more than a few minutes, or that goes away and comes back</dd>
<dt>•</dt>
<dd>severe tightness, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, pressure, or heaviness in your chest, throat, neck, or jaw</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> in your arms, back, neck, jaw, or stomach</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> with or without <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span> </dd>
<dt>•</dt>
<dd>breaking out in a <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">cold sweat</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
<dt>•</dt>
<dd>feeling lightheaded</dd>
</dl>
<p>Sumatriptan Nasal Spray is not for people with risk factors for heart disease unless a heart exam is done and shows no problem. You have a higher risk for heart disease if you:</p>
<dl>
<dt>•</dt>
<dd>have high blood pressure</dd>
<dt>•</dt>
<dd>have high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels</dd>
<dt>•</dt>
<dd>smoke</dd>
<dt>•</dt>
<dd>are overweight</dd>
<dt>•</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></dd>
<dt>•</dt>
<dd>have a family history of heart disease</dd>
</dl>
<p><span class="Bold">What is Sumatriptan Nasal Spray?</span></p>
<p>Sumatriptan Nasal Spray is a prescription medicine used to treat <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> headaches with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> in adults.</p>
<p>Sumatriptan Nasal Spray is not used to treat other types of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> such as hemiplegic (that make you unable to move on one side of your body) or basilar (rare form of <span class="product-label-link" type="condition" conceptid="381549" conceptname="Migraine with aura">migraine with aura</span>) <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>.</p>
<p>Sumatriptan Nasal Spray is not used to prevent or decrease the number of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> you have.</p>
<p>It is not known if Sumatriptan Nasal Spray is safe and effective to treat <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headaches</span>.</p>
<p>It is not known if Sumatriptan Nasal Spray is safe and effective in children under 18 years of age.</p>
<p><span class="Bold">Who should not use Sumatriptan Nasal Spray?</span></p>
<p><span class="Bold">Do not use Sumatriptan Nasal Spray if you have:</span></p>
<dl>
<dt>•</dt>
<dd>heart problems or a history of heart problems</dd>
<dt>•</dt>
<dd>narrowing of blood vessels to your legs, arms, stomach, or kidneys (<span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>)</dd>
<dt>•</dt>
<dd>uncontrolled high blood pressure</dd>
<dt>•</dt>
<dd>severe liver problems</dd>
<dt>•</dt>
<dd>hemiplegic <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span> or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>. If you are not sure if you have these types of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>, ask your healthcare provider.</dd>
<dt>•</dt>
<dd>had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="373503" conceptname="Transient cerebral ischemia">transient ischemic attacks</span> (TIAs), or problems with your blood circulation</dd>
<dt>•</dt>
<dd>taken any of the following medicines in the last 24 hours:<dl>
<dt>•</dt>
<dd>almotriptan (AXERT<span class="Sup">®</span>)</dd>
<dt>•</dt>
<dd>eletriptan (RELPAX<span class="Sup">®</span>)</dd>
<dt>•</dt>
<dd>frovatriptan (FROVA<span class="Sup">®</span>)</dd>
<dt>•</dt>
<dd>naratriptan (AMERGE<span class="Sup">®</span>)</dd>
<dt>•</dt>
<dd>rizatriptan (MAXALT<span class="Sup">®</span>, MAXALT-MLT<span class="Sup">®</span>)</dd>
<dt>•</dt>
<dd>
<span class="Bold">sumatriptan</span> (IMITREX<span class="Sup">®</span>, ALSUMA<span class="Sup">®</span>, SUMAVEL<span class="Sup">®</span>, DosePro<span class="Sup">®</span>, ZECUITY<span class="Sup">®</span>)</dd>
<dt>•</dt>
<dd>sumatriptan and naproxen (TREXIMET<span class="Sup">®</span>)</dd>
<dt>•</dt>
<dd>ergotamines (CAFERGOT<span class="Sup">®</span>, ERGOMAR<span class="Sup">®</span>, MIGERGOT<span class="Sup">®</span>)</dd>
<dt>•</dt>
<dd>dihydroergotamine (D.H.E. 45<span class="Sup">®</span>, MIGRANAL<span class="Sup">®</span>)</dd>
</dl>
</dd>
<dt> </dt>
<dd>	Ask your healthcare provider if you are not sure if your medicine is listed above.</dd>
</dl>
<dl>
<dt>•</dt>
<dd>an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to sumatriptan or any of the ingredients in Sumatriptan Nasal Spray. See below for a complete list of ingredients in Sumatriptan Nasal Spray.</dd>
</dl>
<p><span class="Bold">What should I tell my healthcare provider before using Sumatriptan Nasal Spray?</span></p>
<p>Before you use Sumatriptan Nasal Spray, tell your healthcare provider about all of your medical conditions, including if you:</p>
<dl>
<dt>•</dt>
<dd>have high blood pressure</dd>
<dt>•</dt>
<dd>have high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span></dd>
<dt>•</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></dd>
<dt>•</dt>
<dd>smoke</dd>
<dt>•</dt>
<dd>are overweight</dd>
<dt>•</dt>
<dd>have heart problems or family history of heart problems or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></dd>
<dt>•</dt>
<dd>have kidney problems</dd>
<dt>•</dt>
<dd>have liver problems</dd>
<dt>•</dt>
<dd>have had <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></dd>
<dt>•</dt>
<dd>are not using effective birth control</dd>
<dt>•</dt>
<dd>become pregnant while taking Sumatriptan Nasal Spray</dd>
<dt>•</dt>
<dd>are breastfeeding or plan to breastfeed. Sumatriptan passes into your breast milk and may harm your baby. Talk with your healthcare provider about the best way to feed your baby if you use Sumatriptan Nasal Spray.</dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and nonprescription medicines, vitamins, and herbal supplements.</p>
<p>Sumatriptan Nasal Spray and certain other medicines can affect each other, causing serious side effects.</p>
<p><span class="Bold">Especially tell your healthcare provider if</span> you take anti-depressant medicines called:</p>
<dl>
<dt>•</dt>
<dd>selective serotonin reuptake inhibitors (SSRIs)</dd>
<dt>•</dt>
<dd>serotonin norepinephrine reuptake inhibitors (SNRIs)</dd>
<dt>•</dt>
<dd>tricyclic antidepressants (TCAs)</dd>
<dt>•</dt>
<dd>monoamine oxidase inhibitors (MAOIs)</dd>
</dl>
<p>Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure.</p>
<p>Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I use Sumatriptan Nasal Spray?</span></p>
<dl>
<dt>•</dt>
<dd>Certain people should use their first dose of Sumatriptan Nasal Spray in their healthcare provider’s office or in another medical setting. Ask your healthcare provider if you should use your first dose in a medical setting. </dd>
<dt>•</dt>
<dd>Use Sumatriptan Nasal Spray exactly as your healthcare provider tells you to use it.</dd>
<dt>•</dt>
<dd>Your healthcare provider may change your dose. Do not change your dose without first talking with your healthcare provider.</dd>
<dt>•</dt>
<dd>If you do not get any relief after your first nasal spray, do not use a second nasal spray without first talking with your healthcare provider.</dd>
<dt>•</dt>
<dd>If your <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> comes back after the first nasal spray or you only get some relief from your <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, you can use a second nasal spray 2 hours after the first nasal spray.</dd>
<dt>•</dt>
<dd>Do not use more than 40 mg of Sumatriptan Nasal Spray in a 24‑hour period.</dd>
<dt>•</dt>
<dd>It is not known how using Sumatriptan Nasal Spray for a long time affects the nose and throat.</dd>
<dt>•</dt>
<dd>If you use too much Sumatriptan Nasal Spray, call your healthcare provider or go to the nearest hospital emergency room right away.</dd>
<dt>•</dt>
<dd>You should write down when you have <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> and when you use Sumatriptan Nasal Spray so you can talk with your healthcare provider about how Sumatriptan Nasal Spray is working for you.</dd>
</dl>
<p><span class="Bold">What should I avoid while using Sumatriptan Nasal Spray?</span></p>
<p>Sumatriptan Nasal Spray can cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>. If you have these symptoms, do not drive a car, use machinery, or do anything where you need to be alert.</p>
<p><span class="Bold">What are the possible side effects of Sumatriptan Nasal Spray?</span></p>
<p><span class="Bold">Sumatriptan Nasal Spray may cause serious side effects.</span> See “What is the most important information I should know about Sumatriptan Nasal Spray??</p>
<p>These serious side effects include:</p>
<dl>
<dt>•</dt>
<dd>changes in color or sensation in your fingers and toes (Raynaud’s syndrome)</dd>
<dt>•</dt>
<dd>stomach and intestinal problems (gastrointestinal and colonic ischemic events). Symptoms of gastrointestinal and colonic ischemic events include:<dl>
<dt>•</dt>
<dd>sudden or severe <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> after meals</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></dd>
</dl>
</dd>
<dt>•</dt>
<dd>problems with blood circulation to your legs and feet (peripheral vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>). Symptoms of peripheral vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> include:<dl>
<dt>•</dt>
<dd>cramping and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your legs or hips</dd>
<dt>•</dt>
<dd>feeling of heaviness or tightness in your leg muscles</dd>
<dt>•</dt>
<dd>burning or aching <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your feet or toes while resting</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in your legs</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> feeling or color changes in 1 or both legs or feet</dd>
</dl>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> (<span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span> bumps); <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your tongue, mouth, or throat</dd>
<dt>•</dt>
<dd>medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>. Some people who use too many Sumatriptan nasal sprays may have worse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> (medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>). If your <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> get worse, your healthcare provider may decide to stop your treatment with Sumatriptan Nasal Spray.</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> is a rare but serious problem that can happen in people using Sumatriptan Nasal Spray, especially if Sumatriptan Nasal Spray is used with anti-depressant medicines called SSRIs or SNRIs.</dd>
<dt> </dt>
<dd>Call your healthcare provider right away if you have any of the following symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>:<dl>
<dt>•</dt>
<dd>mental changes such as seeing things that are not there (<span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>), <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span></dd>
<dt>•</dt>
<dd>fast heartbeat</dd>
<dt>•</dt>
<dd>changes in blood pressure</dd>
<dt>•</dt>
<dd>high body temperature</dd>
<dt>•</dt>
<dd>tight muscles</dd>
<dt>•</dt>
<dd>trouble walking</dd>
</dl>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> have happened in people taking Sumatriptan Nasal Spray who have never had <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> before. Talk with your healthcare provider about your chance of having <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> while you take Sumatriptan Nasal Spray.</dd>
</dl>
<p>The most common side effects of Sumatriptan Nasal Spray include:</p>
<dl>
<dt>•</dt>
<dd>unusual or bad taste in your mouth </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> of your throat or nose</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
<dt>•</dt>
<dd>warm, hot, burning feeling</dd>
</dl>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of Sumatriptan Nasal Spray. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store Sumatriptan Nasal Spray?</span></p>
<dl>
<dt>•</dt>
<dd>Store Sumatriptan Nasal Spray between 36°F to 86°F (2°C to 30°C).</dd>
<dt>•</dt>
<dd>Store your medicine away from light.</dd>
</dl>
<p><span class="Bold">Keep Sumatriptan Nasal Spray and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of Sumatriptan Nasal Spray.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflets. Do not use Sumatriptan Nasal Spray for a condition for which it was not prescribed. Do not give Sumatriptan Nasal Spray to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Patient Information leaflet summarizes the most important information about Sumatriptan Nasal Spray. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about Sumatriptan Nasal Spray that is written for healthcare professionals.</p>
<p><span class="Bold">What are the ingredients in Sumatriptan Nasal Spray?</span></p>
<p>Active ingredient: sumatriptan</p>
<p>Inactive ingredients: monobasic potassium phosphate NF, anhydrous dibasic sodium phosphate USP, sulfuric acid NF, sodium hydroxide NF, and purified water USP.</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p>Brands listed are trademarks of their respective owners.</p>
<p>Manufactured by</p>
<p>GlaxoSmithKline Manufacturing S.p.A.</p>
<p>for Sandoz Inc.</p>
<p>Princeton, NJ 08540</p>
<p>June 2014</p>
<p>SNS-SZ:4PPI</p>
<p><span class="Bold">Instructions for Use</span></p>
<p><span class="Bold">Sumatriptan Nasal Spray</span></p>
<p><span class="Bold">For use in the nose only. Do not spray in your eyes.</span></p>
<table width="100%">
<col width="29%">
<col width="71%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center">
<a name="id1742911"></a><img alt="foil_open_color" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6c95caa4-812e-4e47-bcfc-c641c00db3f7&amp;name=sumatriptan-image-04.jpg">
</td>
<td class="Toprule">
<p class="First">Step 1. Remove the Sumatriptan Nasal Spray unit from the plastic pack <span class="Bold">(see Figure A)</span>.</p>
<p>Do not remove the unit until you are ready to use. The unit contains only 1 spray. <span class="Bold">Do not test before use.</span></p>
</td>
</tr>
<tr>
<td align="center"><p class="First"><span class="Bold">Figure A</span></p></td>
<td></td>
</tr>
<tr>
<td align="center">
<a name="id1742912"></a><img alt="figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6c95caa4-812e-4e47-bcfc-c641c00db3f7&amp;name=sumatriptan-image-05.jpg">
</td>
<td><p class="First">Step 2. While sitting down, gently blow your nose to clear your nasal passages <span class="Bold">(see Figure B)</span>.</p></td>
</tr>
<tr>
<td align="center"><p class="First"><span class="Bold">Figure B</span></p></td>
<td></td>
</tr>
<tr>
<td align="center">
<a name="id1742913"></a><img alt="figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6c95caa4-812e-4e47-bcfc-c641c00db3f7&amp;name=sumatriptan-image-06.jpg">
</td>
<td><p class="First">Step 3. Keeping your head in an upright position, gently close 1 nostril with your index finger and breathe out gently through your mouth <span class="Bold">(see Figure C)</span>.</p></td>
</tr>
<tr>
<td align="center"><p class="First"><span class="Bold">Figure C</span></p></td>
<td></td>
</tr>
<tr>
<td align="center">
<a name="id1742914"></a><img alt="Sumatrip nozzle color" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6c95caa4-812e-4e47-bcfc-c641c00db3f7&amp;name=sumatriptan-image-07.jpg"><p class="First"><span class="Bold">Figure D</span></p>
</td>
<td><p class="First">Step 4. With your other hand, hold the container with your thumb supporting the container at the bottom, and your index and middle fingers on either side of the nozzle <span class="Bold">(see Figure D)</span>	.</p></td>
</tr>
<tr>
<td align="center">
<a name="id1742915"></a><img alt="Figure E" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6c95caa4-812e-4e47-bcfc-c641c00db3f7&amp;name=sumatriptan-image-08.jpg"><p class="First"><span class="Bold">Figure E</span></p>
</td>
<td><p class="First">Step 5. Keep your head upright and close your mouth. While gently taking a breath in through your nose, press the blue plunger firmly to release the dose of Sumatriptan Nasal Spray <span class="Bold">(see Figure E)</span>.</p></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center">
<a name="id1742916"></a><img alt="Figure F" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6c95caa4-812e-4e47-bcfc-c641c00db3f7&amp;name=sumatriptan-image-09.jpg"><p class="First"><span class="Bold">Figure F</span></p>
</td>
<td class="Botrule">
<p class="First">Step 6. Keep your head level and remove the nozzle from your nostril. While holding your head level, gently breathe in through your nose and out through your mouth for 10 to 20 seconds <span class="Bold">(see Figure F)</span>.</p>
<p><span class="Bold">Do not breathe in deeply.</span></p>
</td>
</tr>
</tbody>
</table>
<p>This Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.</p>
<p>Brands listed are trademarks of their respective owners.</p>
<p>Manufactured by</p>
<p>GlaxoSmithKline Manufacturing S.p.A.</p>
<p>for Sandoz Inc.</p>
<p>Princeton, NJ 08540</p>
<p>June 2014</p>
<p>SNS-SZ:4PIL</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_1e3f48d4-7376-45be-a766-e7c6ef76d4cc"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">NDC 0781-6524-06</span></p>
<p><span class="Bold">Sumatriptan Nasal Spray</span></p>
<p><span class="Bold">5 mg</span></p>
<p>Each unit dose spray contains 5 mg of sumatriptan. </p>
<p>1 Spray per unit. Do not test before use.</p>
<p>See package insert for full prescribing information.</p>
<p>Store between 36° and 86°F (2° and 30°C).</p>
<p>Protect from light.</p>
<p><span class="Bold">Rx only</span></p>
<p>Manufactured by</p>
<p>GlaxoSmithKline Manufacturing S.p.A.</p>
<p>for Sandoz Inc.</p>
<p>Princeton, NJ 08540</p>
<p>Made in Singapore</p>
<p>10000000055016 Rev. 5/08</p>
<div class="Figure">
<a name="id2823490"></a><img alt="Sandoz Suma NS 5mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6c95caa4-812e-4e47-bcfc-c641c00db3f7&amp;name=sumatriptan-image-10.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_a9a7d82c-d6d0-4121-a302-b884382fd1e6"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPLA DISPLAY PANEL</span></p>
<p><span class="Bold">NDC 0781-6523-06</span></p>
<p><span class="Bold">Sumatriptan Nasal Spray</span></p>
<p><span class="Bold">20 mg</span></p>
<p>Each unit dose spray contains 20 mg of sumatriptan. </p>
<p>1 Spray per unit. Do not test before use.</p>
<p>See package insert for full prescribing information.</p>
<p>Store between 36° and 86°F (2° and 30°C).</p>
<p>Protect from light.</p>
<p><span class="Bold">Rx only</span></p>
<p>Manufactured by</p>
<p>GlaxoSmithKline Manufacturing S.p.A.</p>
<p>for Sandoz Inc.</p>
<p>Princeton, NJ 08540</p>
<p>Made in Singapore</p>
<p>10000000055312 Rev. 5/08</p>
<div class="Figure">
<a name="id2823501"></a><img alt="Sandoz Suma NS 20mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6c95caa4-812e-4e47-bcfc-c641c00db3f7&amp;name=sumatriptan-image-11.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SUMATRIPTAN 		
					</strong><br><span class="contentTableReg">sumatriptan spray</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0781-6524</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">NASAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SUMATRIPTAN</strong> (SUMATRIPTAN) </td>
<td class="formItem">SUMATRIPTAN</td>
<td class="formItem">5 mg  in 100 uL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POTASSIUM PHOSPHATE, MONOBASIC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SULFURIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0781-6524-86</td>
<td class="formItem">6  in 1 BOX</td>
<td class="formItem">09/11/2008</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0781-6524-06</td>
<td class="formItem">100 uL in 1 CONTAINER; Combination Product Type = C102835</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020626</td>
<td class="formItem">09/11/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SUMATRIPTAN 		
					</strong><br><span class="contentTableReg">sumatriptan spray</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0781-6523</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">NASAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SUMATRIPTAN</strong> (SUMATRIPTAN) </td>
<td class="formItem">SUMATRIPTAN</td>
<td class="formItem">20 mg  in 100 uL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POTASSIUM PHOSPHATE, MONOBASIC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SULFURIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0781-6523-86</td>
<td class="formItem">6  in 1 BOX</td>
<td class="formItem">09/11/2008</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0781-6523-06</td>
<td class="formItem">100 uL in 1 CONTAINER; Combination Product Type = C102835</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020626</td>
<td class="formItem">09/11/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sandoz Inc
							(110342024)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f3fdbf09-f9f0-4b55-bdf5-c3175dc1bea4</div>
<div>Set id: 6c95caa4-812e-4e47-bcfc-c641c00db3f7</div>
<div>Version: 9</div>
<div>Effective Time: 20140620</div>
</div>
</div> <div class="DistributorName">Sandoz Inc</div></p>
</body></html>
